Gary Nabel

Gary J. Nabel is the Chief Scientific Officer and Senior Vice President at Sanofi. He completed his undergraduate, MD, and PhD studies at Harvard University (1975, 1980, and 1982, respectively). He completed his dissertation research in the laboratory of immunologist Harvey Cantor and then worked as a postdoctoral fellow in the laboratory of David Baltimore at the Whitehead Institute, studying regulation of HIV gene expression by the recently discovered NF-κB, a host transcription factor.[1] He joined the faculty of the University of Michigan in 1987 and was an HHMI investigator until 1999,[2] working on viral vectors in gene therapy and other subjects. He then served as the inaugural director of the Vaccine Research Center at the NIH before moving to his current position of Sanofi in 2012.[3]

Dr. Nabel was elected into the American Society for Clinical Investigation in 1992 and the National Academy of Medicine in 1998.[4]

See also

References

  • Dolgin, Elie (2013-03-06). "Straight talk with Gary Nabel". Nature Medicine. 19 (3): 256–256. doi:10.1038/nm0313-256. ISSN 1078-8956. Retrieved 2016-12-04.
  • Branswell, Helen (2016-03-17). "Sanofi science chief says it's to time 'think big' about Zika". Retrieved 2017-04-03.
  • Gokhale, Ketaki (2016-07-12). "Sanofi Sees Cure for Cancer Woes in Moving West for Acquisitions". Bloomberg. Retrieved 2017-04-03.
  • Advisory board bio page for the EU-funded Advanced Immunization Technologies project

Notes

  1. ↑ Vincent Racaniello and American Society for Microbiology staff (2016-11-23). Interview with Gary Nabel (MD, PhD) for 'Principles of Virology' 4th Edition. Retrieved 2016-12-05.
  2. ↑ "Gary J. Nabel, former HHMI Investigator" (Text). HHMI.org. Retrieved 2016-12-04.
  3. ↑ Cohen, Jon (2012-11-15). "NIH vaccine chief Gary Nabel trades dream job for big pharma". Science. Retrieved 2016-12-04.
  4. ↑ "Gary J Nabel, MD, PhD". The American Society for Clinical Investigation. Retrieved 2017-04-04.

Selected publications

See Google Scholar for citation information.

  • Nabel, Gary; Baltimore, David (1987-04-22). "An inducible transcription factor activates expression of human immunodeficiency virus in T cells". Nature. 326 (6114): 711–713. doi:10.1038/326711a0. ISSN 0028-0836. Retrieved 2017-04-03.
  • Osborn, L.; Kunkel, S.; Nabel, G. J. (1989-04-01). "Tumor necrosis factor alpha and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kappa B". Proceedings of the National Academy of Sciences. 86 (7): 2336–2340. ISSN 0027-8424. PMID 2494664. Retrieved 2017-04-03.
  • Nabel, G. J.; Nabel, E. G.; Yang, Z. Y.; Fox, B. A.; Plautz, G. E.; Gao, X.; Huang, L.; Shu, S.; Gordon, D.; Chang, A. E. (1993-12-01). "Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans". Proceedings of the National Academy of Sciences. 90 (23): 11307–11311. ISSN 0027-8424. PMID 8248244. Retrieved 2017-04-03.
  • Wu, Xueling; Yang, Zhi-Yong; Li, Yuxing; Hogerkorp, Carl-Magnus; Schief, William R.; Seaman, Michael S.; Zhou, Tongqing; Schmidt, Stephen D.; Wu, Lan; Xu, Ling; Longo, Nancy S.; McKee, Krisha; O’Dell, Sijy; Louder, Mark K.; Wycuff, Diane L.; Feng, Yu; Nason, Martha; Doria-Rose, Nicole; Connors, Mark; Kwong, Peter D.; Roederer, Mario; Wyatt, Richard T.; Nabel, Gary J.; Mascola, John R. (2010-08-13). "Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1". Science. 329 (5993): 856–861. doi:10.1126/science.1187659. ISSN 0036-8075. PMC 2965066. PMID 20616233. Retrieved 2017-04-03.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.